These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 5681014)

  • 1. Induction of tumours in mice and rats with ferric sodium gluconate and iron dextran glycerol glycoside.
    Carter RL; Mitchley BC; Roe FJ
    Br J Cancer; 1968 Sep; 22(3):521-6. PubMed ID: 5681014
    [No Abstract]   [Full Text] [Related]  

  • 2. Attempt to induce tumours by subcutaneous and intraperitoneal administration of Ferridextran (Spofa).
    Braun A; Kren V
    Neoplasma; 1968; 15(1):21-7. PubMed ID: 5650628
    [No Abstract]   [Full Text] [Related]  

  • 3. Early development of injection-site sarcomas in rats: a study of tumours induced by iron-dextran.
    Carter RL
    Br J Cancer; 1969 Sep; 23(3):559-66. PubMed ID: 5360332
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological study in rats of Ferastral, an iron-poly-(sorbitol-gluconic acid) complex, after intramuscular administration.
    Magnusson G; Flodh H; Malmfors T
    Scand J Haematol Suppl; 1977; 32():87-98. PubMed ID: 272039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the oncogenicities of four structurally isomeric N-hydroxyxanthines.
    Teller MN; Budinger JM; Zvilichovsky G; Watson AA; McDonald JJ; Stöhrer G; Brown GB
    Cancer Res; 1978 Jul; 38(7):2038-42. PubMed ID: 207420
    [No Abstract]   [Full Text] [Related]  

  • 7. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy.
    Zager RA
    Kidney Int; 2005 Oct; 68(4):1533-42. PubMed ID: 16164630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [THE EFFECT OF IRON INJECTIONS IN ANIMAL EXPERIMENTS].
    GOLBERG L
    Arzneimittelforschung; 1963 Nov; 13():939-45. PubMed ID: 14210427
    [No Abstract]   [Full Text] [Related]  

  • 9. Do we need to change our administration practice with regard to sodium ferric gluconate complex in glucose?
    Bhowmik D; Tiwari SC
    Nephrol Dial Transplant; 2005 Jun; 20(6):1279. PubMed ID: 15797892
    [No Abstract]   [Full Text] [Related]  

  • 10. The transplantability of the tumour induced in rats by Ferridextran Spofa.
    Kren V; Braun A; Krenová D
    Neoplasma; 1968; 15(1):29-38. PubMed ID: 5655610
    [No Abstract]   [Full Text] [Related]  

  • 11. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
    Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
    Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicological studies on ferastral, an iron-poly-(sorbitol-gluconic acid) complex.
    Flodh H; Magnusson G; Malmfors T
    Scand J Haematol Suppl; 1977; 32():58-68. PubMed ID: 272037
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran.
    Seligman PA; Schleicher RB
    Clin Chem; 1999 Jun; 45(6 Pt 1):898-901. PubMed ID: 10352001
    [No Abstract]   [Full Text] [Related]  

  • 14. INDUCTION OF SARCOMATA IN RABBITS BY INTRAMUSCULAR INJECTION OF IRON-DEXTRAN ("IMFERON").
    HADDOW A; ROE FJ; MITCHLEY BC
    Br Med J; 1964 Jun; 1(5398):1593-4. PubMed ID: 14141626
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on adverse drug events associated with parenteral iron.
    Chertow GM; Mason PD; Vaage-Nilsen O; Ahlmén J
    Nephrol Dial Transplant; 2006 Feb; 21(2):378-82. PubMed ID: 16286429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [AUTORADIOGRAPHIC STUDIES ON MAST CELLS IN IRON DEXTRAN-INDUCED SARCOMA].
    KUNZ J
    Acta Biol Med Ger; 1964; 13():233-8. PubMed ID: 14205277
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect of iron-dextran and ironfree colloid on the distribution of experimental metastases].
    Domellöf L; Boeryd B
    Nord Med; 1970 Oct; 84(42):1348-9. PubMed ID: 5479549
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the carcinogenic actions of subcutaneous implants of iron and aluminum in rodents.
    O'Gara RW; Brown JM
    J Natl Cancer Inst; 1967 Jun; 38(6):947-57. PubMed ID: 6026108
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
    Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
    JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research on the in vivo carcinogenic activity of an iron-dextran complex in the rat].
    VIALLIER J; REBOUILLAT M
    C R Seances Soc Biol Fil; 1962; 156():691-3. PubMed ID: 13925738
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.